SCHEMBL5709288

SCHEMBL5709288

NCc1ccc(COC(N)=O)cc1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 6/20 0.51
PRSS1 P07477 3/20 0.51
TPSD1 Q9BZJ3 1/20 0.51
TPSG1 Q9NRR2 1/20 0.51
ABAT P80404 1/20 0.50
LOXL2 Q9Y4K0 3/20 0.47
PLG P00747 1/20 0.46
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HDAC3 O15379 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
NCOR2 Q9Y618 1/20 0.44
F10 P00742 1/20 0.43
HRH3 Q9Y5N1 1/20 0.42
MAOB P27338 3/20 0.41
PARP10 Q53GL7 1/20 0.41
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30437401 0.91 KMT2A (0.50) MEN1KMT2APARP10ALDH1A1
Benzyl Carbamate SCHEMBL9998168 0.90 ALDH1A1 (0.55) LOXL2KMT2AMAOBALDH1A1
SCHEMBL143772 0.84 MEN1 (0.61) ABATMEN1KMT2AALDH1A1
SCHEMBL20109593 0.84 ENPP2 (0.52) LOXL2PLGALDH1A1
SCHEMBL23533686 0.83 TAAR1 (0.54) KMT2AMAOBALDH1A1
Hydrochloric Acid SCHEMBL29264769 0.83 TPSAB1 (0.51) TPSAB1PRSS1TPSD1TPSG1ABAT
SCHEMBL1934595 0.83 KMT2A (0.44) PRSS1MEN1KMT2APARP10ALDH1A1
SCHEMBL147245 0.83 KMT2A (0.44) LOXL2MEN1KMT2AMAOBPARP10
SCHEMBL21385042 0.81 KMT2A (0.42) MEN1KMT2APARP10ALDH1A1
SCHEMBL113937 0.81 IDO1 (0.54) MEN1KMT2AMAOBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240189440-A1 TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) 2024-06-13 US disclosed
CN-115073467-B Pyrimidine imidazole compound, and pharmaceutical composition and application thereof 中国科学院上海药物研究所 2024-03-15 CN disclosed
EP-4301417-A1 TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES The Research Foundation for The State University of New York (US) 2024-01-10 EP disclosed
CN-117355341-A TLR7 and TLR8 agonists for the treatment of cancer and/or infectious diseases 纽约州立大学研究基金会 2024-01-05 CN disclosed
CN-117177958-A Small molecule modulators of alveolar type 2cell proliferation for the treatment of pulmonary diseases 斯克里普斯研究学院 2023-12-05 CN disclosed
CN-117042782-A Multilayer structure using chemically crosslinked alginic acid 持田制药株式会社 2023-11-10 CN disclosed
CN-116940562-A Acetamido-phenylbenzamide derivatives and methods of use thereof 希华医药有限公司 2023-10-24 CN disclosed
CN-115836054-A IL4I1 inhibitors and methods of use 默沙东有限责任公司 2023-03-21 CN disclosed
CN-108770357-B Polymer conjugate vaccines 芝加哥大学 2022-10-28 CN disclosed
CN-115209920-A Thienoazepine immunoconjugates and uses thereof 博尔特生物治疗药物有限公司 2022-10-18 CN disclosed
CN-114828894-A Polymer-supported thienoazepine compounds and uses thereof 博尔特生物治疗药物有限公司 2022-07-29 CN disclosed
CN-113004283-A Tetracyclic compounds as plasma kallikrein inhibitors and uses thereof 成都康弘药业集团股份有限公司 2021-06-22 CN disclosed
CN-113004286-A Tricyclic compounds as plasma kallikrein inhibitors and uses thereof 成都康弘药业集团股份有限公司 2021-06-22 CN disclosed
CN-111386263-A Modulation of chimeric antigen receptors 达纳-法伯癌症研究所有限公司 2020-07-07 CN disclosed
CN-107257800-B Method for inducing target protein degradation by bifunctional molecules 达纳-法伯癌症研究所股份有限公司 2020-06-30 CN disclosed
CN-110621322-A Modulatable endogenous protein degradation with heterobifunctional compounds 达纳-法伯癌症研究所有限公司 2019-12-27 CN disclosed
CN-109187940-A The preparation and application of a kind of isotopic tag reagent for Analysis of polysaccharides 南京谱利健生物技术有限公司 2019-01-11 CN disclosed
EP-1727790-A1 PHENYLAMINOETHANOL DERIVATIVES AS BETA2 RECEPTOR AGONISTS Pfizer Limited (GB) 2006-12-06 EP disclosed
WO-2005090288-A1 PHENYLAMINOETHANOL DERIVATES AS BETA2 RECEPTOR AGONISTS PFIZER LIMITED (GB) 2005-09-29 WO disclosed
CN-1450915-A Matrix metalloproteinase inhibitors as target components in diagnostic agents BRISTOL MYERS SQUIBB CO (US) 2003-10-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240189440-A1 TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES TLR7, TLR8, TLR9 TPSAB1 934/4885PRSS1 3248/4885TPSD1 1272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.